Cosmetics Regulatory Compliance in Asia-Pacific: NMPA, MFDS, BPOM

On July 15, 2026, China's National Medical Products Administration replaced its 2021 rulebook for new cosmetic ingredients with Announcement No. 59 of 2026, cutting the "higher risk" efficacy category from ten types down to five and letting companies keep certain technical reports on file rather than submit them upfront. Two and a half months later, on October 3, 2026, Indonesia's BPOM Regulation No. 25/2025 reaches its compliance deadline, forcing every cosmetic notified under the old annexes to be reformulated or re-notified if it still contains banned substances like Lilial or D4. Neither deadline made headlines outside the region, and neither one is optional for a brand selling across Asia-Pacific.

That is the defining feature of cosmetics compliance across this region: there is no single regulator, no shared ingredient annex, and no common product classification. China's NMPA, Japan's MHLW and PMDA, South Korea's MFDS, Indonesia's BPOM, Vietnam's Drug Administration, India's CDSCO, and Australia's AICIS each run independent systems that a single formulation can trip in five different ways. A whitening serum that is a plain cosmetic in the EU can require Chinese special-cosmetics registration, Japanese quasi-drug approval, and Korean functional-cosmetics review, three separate dossiers for one product.

Which regulators actually drive cosmetics enforcement in Asia-Pacific?

Seven authorities set the pace, and none of them defers to the others. China's NMPA administers the Cosmetics Supervision and Administration Regulation (CSAR, State Council Order No. 727), splitting products into ordinary cosmetics that only need notification and special cosmetics, covering hair dye, perming, whitening, anti-suntan, and anti-hair-loss claims, that need full registration. Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency regulate cosmetics under the PMD Act, but reclassify anything with a whitening, anti-dandruff, or medicated claim as a quasi-drug requiring individual marketing approval. South Korea's Ministry of Food and Drug Safety runs a comparable functional-cosmetics review under the Cosmetics Act for products claiming to whiten skin, improve wrinkles, or reduce hair loss.

Indonesia's BPOM and Vietnam's Drug Administration of Vietnam both implement the ASEAN Cosmetic Directive at the national level, but on different legal instruments and different timetables. India's CDSCO requires every imported cosmetic to hold an Import Registration Certificate under the Cosmetics Rules, 2020, separate from any Bureau of Indian Standards certification that may apply to specific categories. Australia's AICIS does not regulate finished cosmetics directly; it regulates the industrial chemicals inside them, meaning a business must register with AICIS and correctly categorize every ingredient before importing or manufacturing a single unit.

What changed under China's new cosmetic ingredient rules taking effect in July 2026?

The Regulations on Registration and Filing of New Cosmetic Raw Materials and Management of Documents, NMPA Announcement No. 59 of 2026, took effect July 15, 2026, replacing the 2021 No. 31 rule. It narrows the "higher risk" new-ingredient category from ten efficacy types to five: preservatives, sunscreens, colorants, hair dyes, and freckle-removal or whitening agents, aligning the new-ingredient list with the efficacy ranges that already require registration under the CSAR. Companies no longer have to submit certain technical reports, including function-justification data and accelerated and long-term stability data, upfront; they now keep those on file for inspection instead. The new rule also lets applicants rely on existing safety-use history and internationally recognized animal-alternative test methods rather than repeating toxicology studies already performed under another country's standards.

This sits alongside a separate March 31, 2026 NMPA draft that would extend the animal-testing exemption, in force for imported ordinary cosmetics with a home-country GMP certificate since May 1, 2021, to specific special-use categories: perming products, non-oxidative hair dyes, and freckle-removal or whitening products with purely physical (non-absorbed) coverage. Special cosmetics and any product for infants or children remain outside the exemption entirely, and a brand's domestic responsible person, the NMPA-mandated Chinese legal entity that files registrations and carries recall liability, still needs its authorization renewed at least 30 days before expiry to avoid a filing freeze.

How does Japan's quasi-drug classification change a product's regulatory path?

Japan does not have a single cosmetics ingredient blacklist comparable to the EU's Annexes; instead it runs a hybrid regime of positive lists for UV filters, preservatives, and colorants, and a negative list of prohibited substances, all enforced under the PMD Act. The critical decision point is claims: any product claiming to suppress melanin production, treat acne, or deliver a medicated effect crosses from "cosmetic" into "quasi-drug," a category that requires individual marketing approval from the MHLW, a licensed in-country Marketing Authorization Holder, and, for imported products, an Accreditation of Foreign Quasi-Drug Manufacturer. Selecting an active ingredient with an established approval precedent, such as tranexamic acid, niacinamide, or dipotassium glycyrrhizinate, meaningfully shortens that approval timeline; a novel whitening actives with no precedent triggers a full clinical and safety data package reviewed by the PMDA.

For a brand that markets the same formula as a plain cosmetic in North America or Europe, this reclassification is the most common source of Japan market-entry delay: the claim on the label, not the ingredient itself, decides whether the product needs weeks or many months to clear Japanese approval.

How is the ASEAN Cosmetic Directive being enforced differently across member states in 2026?

The ASEAN Cosmetic Directive sets a regional ingredient baseline through Annexes II (prohibited substances), III (restricted substances), and VII (UV filters), updated as the ASEAN Cosmetic Committee and ASEAN Cosmetic Scientific Body meet, but each member state transposes those updates on its own schedule. Indonesia's BPOM consolidated its national annexes into Regulation No. 25/2025, replacing the 2019 and 2022 rules, with a hard compliance deadline of October 3, 2026: any notified product still containing a newly prohibited ingredient cannot be renewed, and any product exceeding a new restricted-substance limit must be reformulated and re-notified before that date. Vietnam's Drug Administration issued Official Letter No. 647/QLD-MP on February 25, 2026, implementing the 42nd ACC and ACSB meeting outcomes, adding 4-Methylbenzylidene Camphor to the prohibited list (effective November 17, 2028, for Vietnam specifically) while reclassifying it out of the permitted UV-filter annex, and adding concentration limits for genistein and daidzein effective November 17, 2027.

Why does animal testing still block market access in parts of Asia-Pacific, and what is changing?

China remains the clearest example of a market where a product's testing history determines its legal pathway. Since May 1, 2021, imported ordinary cosmetics have qualified for a toxicological test exemption if the manufacturer holds a home-country GMP certificate and the safety risk assessment stands on its own, but special cosmetics, and any product for children, were excluded outright. The March 2026 draft would open a narrow door for select special-use categories, but it remains a proposal, not a rule in force, and NMPA's own September 2025 policy paper frames the broader push, reducing animal testing, promoting alternatives, as a multi-year reform rather than a single rule change. A compliance team assuming the 2021 exemption already covers whitening or hair-dye products is planning against a rule that does not yet exist.

Meanwhile, Australia's AICIS is tightening the other end of the ingredient pipeline: from September 2026, its Industrial Chemicals Categorisation Guidelines add 293 new entries to the high-hazard chemical list and five benzotriazole-related substances to the developmental-toxicity screening step, meaning ingredients that cleared categorization under the current Guidelines may need re-checking before the update takes effect.

What should a compliance team building an Asia-Pacific cosmetics program do next?

The seven-jurisdiction patchwork means no single regulatory calendar can be trusted to cover the region. A realistic program tracks China's registration and filing announcements at the NMPA source, since the July 2026 raw-material rule shows how quickly efficacy categories and documentation requirements can shift; Japan's quasi-drug precedent list, since the claim on a label decides the approval track before a single ingredient is reviewed; the BPOM and DAV implementation notices as each ACC and ACSB meeting cycles through national transposition; and AICIS's annual Categorisation Guidelines update, since an ingredient's hazard status can change every September.

Obsidian tracks each of these tier-0 sources directly, NMPA announcements, MHLW and PMDA notices, MFDS enforcement rule amendments, BPOM regulations, DAV official letters, and AICIS guideline updates, so a compliance team is not left reconciling seven regulators' English-language summaries months after the original text published. Teams can build per-jurisdiction monitoring that flags a new NMPA announcement or an AICIS hazard-list update the day it is issued, ask the AI companion for a direct answer on whether a specific claim triggers Japan's quasi-drug pathway, and pull the same underlying regulatory data into internal tooling through the MCP integration. With China, Indonesia, and Australia all running active rule changes through the second half of 2026, the safer assumption for any regional compliance calendar is that Asia-Pacific cosmetics regulation will keep moving jurisdiction by jurisdiction, not on a single unified schedule.